---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-178755"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2022-06-22T23:59:59+00:00"
generated_at: "2026-06-25T00:00:40.235550+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma Director Cameron Gray Resigns from Board

## Summary
- Cameron Gray notified Cue Biopharma of his resignation as a Board member on June 16, 2022.
- Gray also resigned from all board committees, effective immediately.
- The resignation was not related to any disagreement with the company on operations, policies, or practices.

## SEC filing metadata
- accession: 0001193125-22-178755
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2022-06-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000119312522178755/0001193125-22-178755-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000119312522178755/d535327d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-178755
- JSON: https://secwatch.observer/filing/0001193125-22-178755.json
- Plain text: https://secwatch.observer/filing/0001193125-22-178755.txt

## Key facts
- Executive change
  Cameron Gray resigned as Director at Cue Biopharma, Inc..
  - Action: resigned
  - Role: Director
  source text: On June 16, 2022, Cameron Gray notified Cue Biopharma, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors of the Company (the “Board”) and all committees thereof, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645460/000119312522178755/0001193125-22-178755-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.